Amneal Pharmaceuticals (NYSE: AMRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.130 | 0.120 | -0.0100 | ||||
REV | 503.970M | 497.633M | -6.337M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Amneal Pharmaceuticals (NYSE: AMRX) through any online brokerage.
Other companies in Amneal Pharmaceuticals’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), Aerie Pharmaceuticals (NASDAQ:AERI) and DICE Therapeutics (NASDAQ:DICE).
The latest price target for Amneal Pharmaceuticals (NYSE: AMRX) was reported by Goldman Sachs on Thursday, May 12, 2022. The analyst firm set a price target for 4.50 expecting AMRX to rise to within 12 months (a possible 32.55% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Amneal Pharmaceuticals (NYSE: AMRX) is $3.395 last updated June 27, 2022, 7:59 PM UTC.
There are no upcoming dividends for Amneal Pharmaceuticals.
Amneal Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Amneal Pharmaceuticals.
Amneal Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.